Latest From Valneva SE
Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.
Pivotal trials are underway for two microbiota restoration therapies, a narrow-spectrum antibiotic and a vaccine; funding from non-profits and new owners have revived stalled projects at Summit, Deinove and MGB Biopharma.
Thomas Lingelbach talks to Scrip about Valneva’s plans for a US IPO to fund Phase III studies of its lead Lyme disease vaccine.
Valneva’s 2019 guidance has been boosted by the US Army’s Ixiaro vaccine order, as other products flourish in the pipeline.
- Synthesis Technologies, Production Processes
- Large Molecule
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Valneva SE
- Senior Management
Thomas Lingelbach , Pres. & CEO
David Lawrence, CFO
Franck Grimaud, CBO
Wolfgang Bender, MD, PhD, CMO
- Contact Info
Phone: (33) 2 28 07 37 10
Campus Bio-Ouest | 6, Rue Alain Bombard
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.